ReviewTargeted oncology2011
The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.
Review in Targeted oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.Cellular and molecular life sciences : CMLS · 2024Article
- The effect of dexamethasone on uterine receptivity, mediated by the ERK1/2-mTOR pathway, and the implantation window: An experimental study.International journal of reproductive biomedicine · 2022Article
- Effect of rapamycin on aging and age-related diseases-past and future.GeroScience · 2021Review
- Article
- Article
- Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma.Oncotarget · 2018Article
- The benefit of everolimus in recurrent/epithelioid angiosarcoma patients: Case reports and literature review.Oncotarget · 2017Article
- Managing sarcoma: where have we come from and where are we going?Therapeutic advances in medical oncology · 2017Review
- Review
- Primary Angiosarcoma of the Breast: An Uncommon Histopathological Subtype.Journal of clinical and diagnostic research : JCDR · 2015Article
- Article
- P70S6 kinase phosphorylation: a new site to assess pharmacodynamy of sirolimus.Chinese medical journal · 2015Article
- Primary angiosarcoma of breast: A case report.International journal of surgery case reports · 2013Article
- Treatment of Bone Tumors.Surgical pathology clinics · 2012Article
- P2X7 Receptor Function in Bone-Related Cancer.Journal of osteoporosis · 2012Article
- Article
- Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.Targeted oncology · 2011Review
- Are we ready to move away from nature?: the rapamycin story.Targeted oncology · 2011Article
- Targeting the target of rapamycin (TOR): looking to mother nature.Targeted oncology · 2011Article
- Primary breast angiosarcoma: avoiding a common trap.Case reports in oncological medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
The mammalian target of rapamycin (mTOR) is a protein kinase that functions as a key regulator of cell growth, proliferation and differentiation, cell-cycle progression, angiogenesis, protein degradation, and apoptosis. Following activation by a number of oncogenic signals such as growth factors, energy and nutrients, mTOR stimulates several downstream effectors including the 40S ribosomal protein S6 kinase (p70s6k) and the eukaryotic initiation factor 4 E binding protein-1 (4 EBP-1), as well as a complex network of regulatory loops. Activation of the mTOR pathway plays a critical role in the development of many tumor types, including renal cell and breast carcinomas, neuroendocrine tumors, and sarcomas. Bone and soft tissue sarcomas are rare, heterogeneous tumors that are curable by local treatments if diagnosed at early stages; however advanced or metastatic sarcomas are rarely curable and very few drugs are efficacious in this setting. Several disruptions in phosphatidylinositol-3 kinase (PI3K)-Akt-mTOR signaling are associated with malignant transformation or progression in various sarcoma sub-types. The PI3K-Akt-mTOR pathway is therefore an exciting target for therapy of sarcomas, and its blockade represents an opportunity to improve outcomes in this poor-prognosis disease. Early studies with mTOR inhibitors have demonstrated promising antitumor activity in patients with metastatic sarcoma who have failed standard treatments. This article discusses the mTOR signaling pathway and summarizes the clinical experience with mTOR inhibitors in patients with advanced or metastatic sarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.